Overview:
Niemann-Pick disease type C (NPC) is a rare, progressive lysosomal disorder with a heterogeneous, age-dependent presentation that often delays diagnosis while irreversible neurologic decline accumulates. Advances in biomarker and comprehensive genomic testing, together with an expanding set of disease-modifying therapies, have changed the clinical pathway for NPC. They have also created uncertainty about when to move beyond targeted testing and how to time, individualize, and monitor treatment over the long term.
This CME-accredited, live (and
online) satellite symposium, held in conjunction with WORLDSymposium 2027, brings together a multidisciplinary faculty panel to discuss case-based
strategies for integrating clinical, biochemical, and genomic findings into an
accurate diagnosis, and for optimizing treatment initiation and long-term,
multidisciplinary management of patients with NPC.
Learning Objectives:
Upon
completion of this activity, participants will be able to:
- Apply evidence-based approaches to incorporate comprehensive genomic testing into the diagnostic evaluation of patients with suspected NPC
- Implement evidence-based strategies to optimize treatment initiation and long-term management for patients with NPC
Target Audience:
This
educational curriculum is directed toward pediatric neurologists, medical
geneticists, metabolic specialists, genetic counselors, NPs, PAs, and other
healthcare professionals involved in the management of patients with Niemann-Pick
Disease Type C (NPC).
Elizabeth Berry-Kravis, MD, PhD
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity
for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.

